cyrilzakka/clinical-trials huggingface dataset:
Walking Ankle isoKinetic Exercise

This study is a multi-center, interventional, experimental, prospective, controlled and randomized study. We propose a reeducation protocol based on an early over-solicitation of the ankle dorsiflexor muscles to promote their "awakening", limit the loss of strength associated with the functional loss and thus allow to reach a more effective walking activity. This should encourage social participation following discharge from the hospital. The main objective is to evaluate the impact of this 6 weeks program on walking speed.

According to HAS, stroke is the leading cause of disability acquired in France. If 90% of patients recover walking, it is often limited with a steady speed around 0.7m/s. This limitation of walking activity is partly related to a decrease in strength associated with more or less significant spasticity. In stroke, this decrease in strength is the result of central impairment. Rehabilitation therefore involves gestural repetition. Mentiplay's review (Mentiplay et al., 2015) showing the predominance of ankle muscle strength in walking activity, we propose a protocol based on repetitive mobilization of this joint during subacute phase to promote awakening control, to limit the loss of muscle strength and thus potentiate the recovery of a more efficient walking. The strength of this study would be to verify the effectiveness of such a program in a large number of patients (5 centers involved). Its originality is to measure the impact of this program on social participation.

The patients will be recruited in 5 centers during their hospitalization, in sub-acute phase. Two groups will be formed: a control group in conventional rehabilitation; an experimental group that will perform 5x/week 300 movements of plantarflexion, dorsiflexion on isokinetic dynamometer (in passive mode, with the intention of producing the greatest possible force). This protocol will take place over 6 weeks.

Follow-up visits will take place at the end of the 6th week (which corresponds to the end of the ankle rehabilitation protocol), 6 months and one year after the beginning of the protocol.

These visits will include a clinical examination, a GaitRite carpet walking test, an isokinetic evaluation of the ankle dorsiflexor muscles strength and a SIPSO self-administered questionnaire (social participation) at 6 months and one year.

Eligibility Criteria:
Inclusion Criteria:

* First stroke,
* Ischemic or hemorrhagic stroke hospitalized in MPR in sub-acute phase (15 days to 3 months)
* Persistent deficiency of foot lifts (Medical Research Council testing: MRC \<5)
* Walking alone at least 10 meters with or without technical assistance
* Absence of pain in the lower limb (EVA \<2)

Exclusion Criteria:

* Cognitive or phasic disorders that do not make it possible to understand the instructions: Boston Scale BDAE \<2
* Gait disorder before stroke
* Fixed stiffness of the ankle (irreducible equine less than 30 °)
* Spasticity too important: Modified Ashworth (MAS) greater than or equal to 4.
* Pregnancy or desire for pregnancy, breastfeeding
* Patient under curatorship or guardianship or under the protection of justice
Patient Satisfaction and Peri-Implant Tissue Success of Hybrid Ceramic Versus E-Max Superstructures

In patients receiving implants in the esthetic zone, would the use of new Nano hybrid ceramic crown material (Crystal Ultra) improve esthetic patient satisfaction and peri-implant tissue success when compared with Lithium Disilicate crown (E-max)?

The patient will be treated in visits designated as follows:

Visit 1: Preoperative records, face-to-face adherence reminder session, signing consents, clinical, radiographic examination and primary impression for diagnostic cast construction.

Visit 2: (first stage surgery): implant placement surgical procedure and postoperative radiograph.

Visit 3: After 3months (second stage surgery): re-opening of surgical site, placement of healing abutments and temporary crowns.

Visit 4: After 2 weeks, removing of temporary restorations and taking of final impressions Visit 5: placement of different ceramic crown superstructures and recording different outcome values.

Eligibility Criteria:
Inclusion Criteria:

1. Age above 18 years with at least one tooth missing in the esthetic area.
2. Available bone for implant placement:

   A. Labial and Palatal Plate of bone not less than 2mm. B. Mesio- distal dimension not less than 6.5mm. C. Bone length not less than 9mm.
3. Patient with good oral hygiene.
4. Class 1 occlusion.
5. Lack of excessive parafunctional activity leading to implant failure.
6. Tooth extracted not less than 6 month.

Exclusion Criteria:

1. Young patients in whom the jaws are still growing. (Less than 18 years).
2. Jaw pathology.
3. Smokers.
4. Uncontrolled Diabetic or particularly insulin-dependent.
5. Radiotherapy to the neck or face.
6. Multiple loss of teeth which may be indicated for more complicated procedure.
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI

Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study is to research that the incidence of adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction is significantly higher when the glomerular filtration rate below a certain value.

The investigators retrospectively analyzed the clinical data of 1157 patients with ST-segment elevation myocardial infarction. In-hospital adverse cardiovascular events (MACE) was defined as: cardiac arrest, cardiac rupture, malignant arrhythmia, and cardiac death. All the patients were divided into 3 groups according to the patient's estimated glomerular filtration rate(eGFR) (eGFR≥90ml/min/1.73m2; 90ml/min/1.73m2\>eGFR≥60ml/min/1.73m2; eGFR\<60ml/min /1.73m2). COX regression analysis and K-M survival curves are used to calculate the correlation between eGFR and in-hospital MACE.

Eligibility Criteria:
Inclusion Criteria:

* 1.Patients with STEMI 2.Patients from whom informed consent has been properly obtained in writing prior to start of the trial

Exclusion Criteria:

* 1.Patients with previous myocardial infarction, congenital heart disease 2.Patients with liver disease, and renal failure 3.Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.
Exercise and Neural Response to Food Cues in Children

Physical exercise has been shown to significantly reduce subsequent energy intake in obese adolescents but not in lean, without altering their appetite feelings. Although previous studies have pointed out the role of gastric peptides in this post exercise nutritional response, some recent work question the role of the neural system in the post exercise drive to eat. This study tends to explore whether or not an acute bout of exercise can affect the neural response to food cues in adolescents, obese or lean.

After a medical inclusion, the adolescents will have to realise a DXA to assess their body composition and a submaximal exercise to evaluate their aerobic capacities.

They will have then to enter the laboratory on 2 different occasions in a randomized order from 8am to 330pm: At 8am they will receive a calibrated breakfast. then, at 1045; they will have to complete one of the experimental condition: 1) a cycling exercise or 2) remaining sitting fpr one hour. after the one hour sitting station or the exercise bout, they will be asked to complete a computer task while and electroencephalogram will be recorded. This computer task consists in visual recognition of rare pictures compared to frequent ones (oddball method). at 1215 they will be offered ad libitum meals. At regular intervals through the day, their appetite feelings will be assessed using Visual analogue scales.

Ad libitum energy consumption will be assessed by investigators and recorded for each participants.

Eligibility Criteria:
Inclusion Criteria:

* male
* 12-15 years old
* BMI defining obesity (Cole et al., 2000)
* Not being under diet restriction
* Information and consent forms have to be signed by the adolescent and his legal representative
* being registered to the national social security system

Exclusion Criteria:

* Being under medication
* contraindication to exercise
* smokers
* dieting
Quality of Life of Patients With Pregnancy Related VTE

A retrospective study of the quality of life and problems experienced by patients who developed pregnancy related VTE. It involves patients seen at JUH in 2012-2020. A questionnaire will be filled by those patients and any other patients in Jordan. It was translated to an Arabic form from EQ-5D, VEINES-QOL/SYM questionnaire and PEmb-QoL. The quality of their lives will be assessed and the problems encountered are going to be analyzed to try to find some solutions. This project is going to be a national research project with the efforts to try to find common platforms for those patients and nidus to establish a national support group.

Retrospective study and analysis using a questionnaire which will be distributed to patients. The patients' data and contact details (phone numbers, whatsApp, email address...) will be collected from their clinical records at the JUH hospital. The period 2012-2020 will be covered. The questionnaire link is; file:///C:/Users/user/Downloads/QoL-post-VTE-during-pregnancy-5.pdf and file:///C:/Users/user/Downloads/arabic%20questionnaire%20last%201.pdf

Eligibility Criteria:
Inclusion Criteria:

* pregnancy related event
* confirmed diagnosis by an objective diagnostic tool (Duplex ultrasonography, CT pulmonary angiography, spiral CT scan or ventilation perfusion scan)
* consent (acceptance) to participate was obtained
* alive patients

Exclusion Criteria:

* death
* an objective diagnostic tool could not be found to confirm the diagnosis
* their event was not related to pregnancy
* refusal to participate
The Life Experience of Young Women (Age 18-38) Who Live With Congenital Heart Disease

This research will focus on young women between the ages of 18-38 who underwent a heart operation and their life experiences. This research will focus on these life events and the paradigm of these women being raised as "heart sick," and consequently lacking self-esteem (Frigiola, Bull, \& Wray, 2014; Hickey et al., 2012). Most qualitative studies focusing on the quality of life compare men and women, completely ignoring women's body image and the experience of womanhood (Hickey et al., 2012; Hövels-Gürich et al., 2007; Sarikouch, et al., 2013). This study aims to focus on women's stories about their life experiences and the influence of surgery(ies) on their daily life using an the qualitative phenomenological approach.


Eligibility Criteria:
Inclusion Criteria:

* Atrial septal defect or ASD,
* Ventricle septal defect or VSD,
* Tetralogy of Fallot or TOF
* Translocation of great arteries or TGA
* underwent heart operation
* Hebrew speakers that are able to understand the meanings of the questions and tell their life stories.

Exclusion Criteria:

* Non Hebrew speakers
* Did not underwent heart surgery.
Biological Markers Evaluation of Accelerated Tooth Movement

Gingival Crevicular Fluid samples will be collected using periopapers after accelerated tooth movement technique, results will be assessed with biomarkers levels done using ELISA Assays

For this prospective study, 22 individuals were selected, with skeletal discrepancies randomly divided into two groups: 1 - accelerated tooth movement technique (ATMT) and 2 - Control.

Orthodontic records done in two times, initial and preoperative; Gingival Crevicular Fluid samples will be collected using periopapers in 7 times (1, 2, 7, 14, 28 days and after space closure- end of orthodontic treatment movement activation).

Flapless cortical perforations will be made in ATMT Group after dental extraction. Surgical protocol will be flapless to preserve periodontal health.

After extraction space closure, results will be assessed by clinical effects with biological markers levels:

CCL3/MIP-1 alpha, CCL5/RANTES, CXCL8/IL8, IL-1 alpha, IL-1 beta, IL6, TNF-alpha, TRANCE/RANK L, OCN OPG IL-10 VEGF TGF-ℬ

Those biomarkers levels will be performed using ELISA Assays. After collecting data, the results will be statistically analyzed using Shapiro-Wilk and, posteriorly, T-student or Wilcoxon.

Eligibility Criteria:
Inclusion Criteria:

* Adult subjects ages 18-40 years old, in good general health, with adult complete dentition, regardless of presence of third molars.
* Indication for orthognathic surgery
* Tooth extraction indication for orthodontic treatment
* Do not smoke
* Periodontal and teeth healthy
* Do not use bisphosphonates or corticosteroids

Exclusion Criteria:

* Surgically assisted rapid palatal expansion indication
* Cleft lip and palate
* Craniofacial syndrome
* Mental disorder
* Metabolic diseases
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in addition to the standard chemotherapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium by estimating the time to progression.


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically-confirmed transitional cell carcinoma of the urothelium
* Locally advanced or metastatic disease
* At least one measurable lesion as defined by RECIST
* Chemotherapy-naiv

Exclusion Criteria:

* Previous chemotherapy or other systemic antitumour therapy
* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma, cervical cancer in situ or locally limited prostate cancer
Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.

Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).


Eligibility Criteria:
Participants with chronic kidney disease undergoing hemodialysis Inclusion criteria

* Age \>18 years
* Chronic kidney disease
* Hemodialysis

Exclusion criteria:

- Acute kidney disease

Participants with chronic kidney disease, not in dialysis Inclusion criteria

* Age \>18 years
* Chronic kidney disease (eGFR from \<15 to 44)

Exclusion criteria:

* Acute kidney disease
* Hemodialysis
* Peritoneal dialysis

Participants with chronic kidney disease undergoing peritoneal dialysis Inclusion criteria

* Age \>18 years
* Chronic kidney disease
* Peritoneal dialysis

Exclusion criteria:

- Acute kidney disease

Healthy volunteers Inclusion criteria

* Age \>18 years
* Blooddonors

Exclusion criteria:

- NA
Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration

The rational of the study is to assess the implantation, pregnancy and live birth rates after the transfer of frozen- thawed embryos in natural cycles with spontaneous Luteinizing Hormone (LH)/Progesterone rise or in natural cycles controlled by human chorionic gonadotropin (hCG) for final oocyte maturation and ovulation.


Eligibility Criteria:
Inclusion Criteria:

* age \<40
* BMI:18-29Kg/m2
* day 3 embryo transfers
* previously IVF or ICSI

Exclusion Criteria:

* irregular cycles
* oocyte donation cycles
Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)

This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated catheters. Urine and/or catheter DNA analysis will be obtained at catheter insertion, 2, 5, 7 and 14 days after catheterization.

This is a 2-week, single-site, randomized controlled pilot study in adults requiring short-term \< 14 days catheterization. Subjects will be randomized 1:1 to either the BLASTX or SOC lubricated catheters.

Urine and catheter DNA analysis will be obtained at catheter insertion, 2 to 3 days after catheterization and at 5, 7 and 14 days if catheterization was indicated for either duration.

Informed consent discussion will be completed, ICF will be signed, prior to any study procedures.

Subjects will be included only if all of the inclusion criteria and none of the exclusion criteria have been met.

After randomization, subjects will be followed, urine samples will be collected at each scheduled visit and the catheters will be collected upon removal.

Eligibility Criteria:
Inclusion Criteria:

1. 18 years or older
2. Absence of symptomatic UTI
3. Absence of upper/lower tract obstructions
4. No known allergies to the study products
5. Willing to comply with all study procedures and available for the duration of the study

Exclusion Criteria:

1. 17 years or younger
2. Symptomatic UTI
3. Presence of upper/lower tract obstructions
4. Known allergic reaction to the study products
5. Unable to provide signed and dated informed consent form
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

This study will evaluate the safety and immunogenicity in healthy children and adolescents after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.


Eligibility Criteria:
Inclusion Criteria:

* Males and females aged 3 to 17 years, in good health as determined by medical history, physical examination and clinical judgment of the investigator
* Documented consent provided by parents or legal guardians
* For individuals 8 years of age and older, informed assent to participate in the study after the nature of the study had been explained to them in terms they could understand
* Individuals and parents/guardians who were able to comply with all study procedures and were available for all clinic visits scheduled in the study

Exclusion Criteria:

* Parents or legal guardians and individuals who are not able to comprehend and to follow all required study procedures for the whole period of the study
* Parents or legal guardians and individuals providing assent who do not consent to the retention of the subject's serum samples after study completion
* Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may have interfered with the subject's ability to participate in the study
* Individuals with history or any illness that, in the opinion of the investigator, might have interfered with the results of the study or posed additional risk to the subjects due to participation in the study
* History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, latex, to any excipients, and to eggs (including ovalbumin), chicken protein, influenza viral protein, kanamycin, neomycin sulphate, cetyltrimethylammonium bromide (CTAB), polysorbate 80, neomycin, polymixin, formaldehyde, thimerosal, beta propiolactone, or nonoxynol-9
* History of any serious disease, such as:

  1. cancer
  2. history of serious chronic, rheumatologic, neurologic and hematologic diseases
  3. history of underlying medical condition such as inborn errors of metabolism
* Known or suspected impairment/alteration of immune function, including:

  1. chronic use of oral steroids within 60 days prior to Visit 1 (use of inhaled, intranasal, or topical corticosteroids is allowed)
  2. receipt of immunostimulants within 60 days prior to Visit 1
  3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within 3 months prior to Visit 1 or planned during the full length of the study
  4. HIV infection or HIV-related disease
* Pregnant or breast-feeding female and any positive or indeterminate pregnancy test
* Received an influenza vaccine within 6 months prior to Visit 1
* Laboratory-confirmed or suspected influenza disease within 6 months prior to Visit 1
* Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study
* Experienced a fever and/or any acute illness within 3 days prior to each study vaccination
Comparison of Transtibial and Transfemoral Amputees' Posture Parameters

With the onset of prosthesis use following lower extremity amputations, body shows biomechanical changes according to the amputation level and consequently develops adaptation mechanisms both on the healthy and ampute side. The aim of this study is to determine the static postural adaptations that appear at different amputation levels.


Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-65
* Having had an amputation at least 6 months ago
* Have had transfemoral amputation or transtibial amputation
* To be able to perform ambulation independently

Exclusion Criteria:

* mental inability to understand commands
* have a neurological, orthopedic and systemic problem that will negatively affect posture or gait.
Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)

The objective of this study is to evaluate effectiveness and safety of XIENCE PRIME stent in the "real world" daily practice as compared with other drug eluting stents (DESs)

This study is a non-randomized, prospective, open-label registry to compare the effectiveness and safety of XIENCE PRIME stents versus other DESs in patients with coronary artery disease.

Eligibility Criteria:
Inclusion Criteria:

* Patients receiving XIENCE PRIME stents.
* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion Criteria:

* Patients with a mixture of other DESs
* Terminal illness with life expectancy \<1 year
* Patients presented with cardiogenic shock